Ichnos Glenmark Innovation (IGI) and AbbVie Announce Exclusive Global Licensing Agreement for ISB 2001, a First-in-Class CD38×BCMA×CD3 Trispecific Antibody
NEW YORK and NORTH CHICAGO, Ill., July 10, 2025 (GLOBE NEWSWIRE) -- IGI Therapeutics SA, a wholly owned subsidiary of New York-based Ichnos Glenmark Innovation, Inc. (IGI), and AbbVie (NYSE: ABBV) today announced an exclusive licensing agreement for IGI's lead investigational asset, ISB 2001, developed using IGI's proprietary BEAT® protein platform, for oncology and autoimmune diseases.
'Multispecifics including trispecific antibodies represent a new frontier in immuno-oncology with the potential to deliver deeper, more durable responses by engaging multiple targets simultaneously,' said Roopal Thakkar, M.D., Executive Vice-President, Research and Development and Chief Scientific Officer, AbbVie. 'This partnership with IGI reflects our unwavering commitment to advancing novel therapies for patients with multiple myeloma, a disease where significant unmet need remains despite recent progress.'
'ISB 2001 exemplifies the potential of our BEAT® protein platform to generate effective multispecifics™ that may overcome resistance and improve outcomes in hard-to-treat cancers,' said Cyril Konto, M.D., President and CEO of IGI. 'This agreement marks a defining milestone in IGI's scientific journey and reflects our team's deep commitment to delivering meaningful therapies for patients, Our partnership with AbbVie accelerates ISB 2001's path to patients and sharpens our focus on advancing th e next generation of BEAT®-enabled assets in oncology.'
Under the terms of the agreement, AbbVie will receive exclusive rights to develop, manufacture, and commercialize ISB 2001 across North America, Europe, Japan, and Greater China. Subject to regulatory clearance, IGI will receive an upfront payment of $700 million and is eligible to receive up to $1.225 billion in development, regulatory, and commercial milestone payments, along with tiered, double-digit royalties on net sales.
About ISB 2001
ISB 2001 is a first-in-class trispecific T-cell engager that targets BCMA and CD38 on myeloma cells and CD3 on T cells currently in Phase 1 for relapsed/refractory multiple myeloma. Developed using IGI's proprietary BEAT® protein platform, ISB 2001 was engineered with two distinct binders against myeloma-associated antigens to enhance avidity, even at low target expression levels, while aiming to improve safety over first-generation bispecific antibodies. Recently presented at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting as a Rapid Oral Presentation (Abstract #7514), data from 35 patients demonstrated a sustained overall response rate (ORR) of 79% and a high complete/stringent complete response (CR/sCR) rate of 30% at active doses ≥ 50 µg/kg in a heavily pretreated population of relapsed/refractory myeloma patients, with a favorable safety profile.
U.S. Food & Drug Administration granted ISB 2001 Orphan Drug Designation in July 2023 and Fast Track Designation for the treatment of relapsed/refractory myeloma patients in May 2025.
About the BEAT® Multispecific™ Platform
IGI's proprietary BEAT® platform goes beyond traditional bispecific antibody approaches, addressing key engineering bottlenecks that have historically limited large-scale bispecific production. By leveraging a proprietary common light chain library and TCR interface-based heavy chain pairing, BEAT® enables the development of next-generation immune cell engagers with strong therapeutic potential in oncology. Unlike many engineered formats, BEAT® mirrors the architecture of natural antibodies utilizing both light and heavy chains to enhance stability and function. Key attributes of the BEAT® platform include its multispecific versatility, enabling the design of antibodies that engage diverse immune cell types such as T cells, myeloid cells, and NK cells against multiple antigens. The platform also features optimized engineering through high-fidelity heavy chain pairing with a common light chain, allowing for precise Fc modulation and access to a broad structural design space. Additionally, BEAT® supports robust manufacturability, producing correctly assembled multispecific antibodies with favorable stability, extended half-lives, low immunogenicity and high titer yields through standardized process development and manufacturing operations.
About IGI
IGI is a global, fully integrated clinical-stage biotechnology company focused on developing innovative biologics in oncology. Headquartered in New York, NY, IGI is advancing a robust pipeline of novel, first-in-class multispecifics™ aimed at addressing complex diseases and treating patients holistically. Powered by its proprietary BEAT® technology platform, IGI is committed to delivering breakthrough, curative therapies to improve and extend the lives of patients battling hematological malignancies and solid tumors. For more information, visit www.IGInnovate.com.
About AbbVie
AbbVie's mission is to discover and deliver innovative medicines and solutions that solve serious health issues today and address the medical challenges of tomorrow. We strive to have a remarkable impact on people's lives across several key therapeutic areas – immunology, oncology, neuroscience, and eye care – and products and services in our Allergan Aesthetics portfolio. For more information about AbbVie, please visit us at www.abbvie.com. Follow @abbvie on LinkedIn, Facebook, Instagram, X (formerly Twitter), and YouTube.
About AbbVie in Oncology
AbbVie is committed to elevating standards of care and bringing transformative therapies to patients worldwide living with difficult-to-treat cancers. We are advancing a dynamic pipeline of investigational therapies across a range of cancer types in both blood cancers and solid tumors. We are focusing on creating targeted medicines that either impede the reproduction of cancer cells or enable their elimination. We achieve this through various, targeted treatment modalities and biology interventions, including small molecule therapeutics, antibody-drug conjugates (ADCs), immuno-oncology-based therapeutics, multispecific antibody and novel CAR-T platforms. Our dedicated and experienced team joins forces with innovative partners to accelerate the delivery of potential breakthrough medicines.
Today, our expansive oncology portfolio comprises approved and investigational treatments for a wide range of blood cancers and solid tumors. We are evaluating more than 35 investigational medicines in multiple clinical trials across some of the world's most widespread and debilitating cancers. As we work to have a remarkable impact on people's lives, we are committed to exploring solutions to help patients obtain access to our cancer medicines. For more information, please visit http://www.abbvie.com/oncology.
AbbVie Forward Looking Statement
Some statements in this news release are, or may be considered, forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995. The words "believe," "expect," "anticipate," "project" and similar expressions and uses of future or conditional verbs, generally identify forward-looking statements. AbbVie cautions that these forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those expressed or implied in the forward-looking statements. Such risks and uncertainties include, but are not limited to, challenges to intellectual property, competition from other products, difficulties inherent in the research and development process, adverse litigation or government action, changes to laws and regulations applicable to our industry, the impact of global macroeconomic factors, such as economic downturns or uncertainty, international conflict, trade disputes and tariffs, and other uncertainties and risks associated with global business operations. Additional information about the economic, competitive, governmental, technological and other factors that may affect AbbVie's operations is set forth in Item 1A, "Risk Factors," of AbbVie's 2024 Annual Report on Form 10-K, which has been filed with the Securities and Exchange Commission, as updated by its Quarterly Reports on Form 10-Q and in other documents that AbbVie subsequently files with the Securities and Exchange Commission that update, supplement or supersede such information. AbbVie undertakes no obligation, and specifically declines, to release publicly any revisions to forward-looking statements as a result of subsequent events or developments, except as required by law.
IGI Corporate CommunicationsCorporate.communications@IGInnovate.com
AbbVie Investor and Media ContactsMedia Sourojit (Jit) Bhowmick, Ph.D.jit.bhowmick@abbvie.com
InvestorsLiz Shea liz.shea@abbvie.com
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
San Francisco Chronicle
11 minutes ago
- San Francisco Chronicle
California's major home insurers are likely to raise rates soon. Here's why
California home insurance companies could begin requesting rate increases within weeks, after state regulators approved a key step that will undergird new rate filings. Insurance rates have soared in California in recent years, but insurers say they still don't reflect the cost of doing business in the expensive, wildfire-prone state. To prevent insurers from further pulling back coverage or leaving the state, the California Department of Insurance recently enacted a set of reforms, called the Sustainable Insurance Strategy, that will make it easier for insurers to justify rate increases — though the state plans to ensure that the carriers continue to cover, and even expand, in parts of the state considered at risk for wildfires. A key step in the reform process occurred last week, when the Department of Insurance said it would allow insurers to use a catastrophe model to evaluate future risks. Previously, insurers have only been allowed to use backwards-looking information as the basis for rate increase requests — and thus could not take global warming or other predicted future changes into account. Insurers and regulators have long said that a more accurate assessment of future risks is critical for them to remain viable in California. California is an outlier: Other states already allow carriers to forecast risks using catastrophe models. The newly approved model was created by the New Jersey company Verisk. Two other catastrophe models, made by Moody's and Karen Clark, are now under review, according to Deputy Insurance Commissioner Michael Soller. 'I'm expecting (that) within a matter of weeks we could have our first filing from a major carrier,' Soller said in an interview Thursday. Exactly how much rates are likely to rise in the immediate future is unknown, and will undoubtedly vary by insurer. Mercury, a Los Angeles-based insurer that is one of California's largest carriers, said it is currently preparing a rate change request for homeowners insurance using the Verisk model. 'The move is a direct result of the ongoing implementation of (Insurance Commissioner Ricardo Lara's) Sustainable Insurance Strategy, which the company believes will provide California homeowners with more insurance options and lead to a more resilient insurance marketplace,' the company said. The use of catastrophe models is one of several key changes made by Lara under his Sustainable Insurance Strategy. Another key change is allowing insurers to partially pass on the cost of reinsurance (insurance for insurance companies) to policyholders — something not previously allowed in California, though it is common in other states. As soon as they file for updated rates, insurance companies will be required to tell regulators if they plan to write new policies, and if so, how many new policies. Insurers will also be asked to describe how they'll be seeking new policies to write — for example, if they'll offer full coverage to customers whom they partially cover under a companion policy to California's FAIR plan. (The FAIR Plan is California's insurer of last resort and covers only damage from wildfires, whereas traditional insurers include other risks such as liability and plumbing problems.) There have been virtually no rate increase requests filed after the devastating Los Angeles wildfires in January. In prior years, large rate increase requests tended to flow in after major fires, Soller said. But this time, insurers have been waiting for the catastrophe models to be approved. 'It's why we are doing this,' Soller said, noting that really large rate increases after wildfires are 'not a sustainable path for us.'
Bloomberg
12 minutes ago
- Bloomberg
Uber Says New NYC Courier Rule ‘Singles Out' Immigrant Workers
Uber Technologies Inc. is pushing back on a new NYC proposal requiring delivery app workers to display company-issued identification numbers on reflective vests, saying it 'singles out' immigrant workers for 'heightened surveillance and control.' The new rules, proposed Monday by Mayor Eric Adams in the name of worker safety, would mandate that companies like Uber and DoorDash Inc. issue identification cards containing a unique number alongside the name and photo of each courier. They would be required to produce it upon demand of a police officer or others 'authorized by law.'
Yahoo
23 minutes ago
- Yahoo
Mathieu Darche Brings Trusted Equipment Manager From Lightning To Islanders
Although New York Islanders general manager Mathieu Darche finalized his final player contract when he avoided salary cap arbitration with Maxim Tsyplakov this past Friday, Darche has made one final signing.
